HUTCHMED (China) Ltd
HCM15.440USD
+0.130+0.85%
Fechamento 11/04, 16:00（ET）Cotações atrasadas em 15 min
13.47BValor de mercado
--P/L TTM
Mais detalhes de HUTCHMED (China) Ltd Empresa
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Informações de HUTCHMED (China) Ltd
Código da empresaHCM
Nome da EmpresaHUTCHMED (China) Ltd
Data de listagemMay 19, 2006
CEODr. Weiguo Su, Ph.D.
Número de funcionários1811
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 19
Endereço48th Floor, Cheung Kong Center, 2 Queen's Road Central
Cidade
Bolsa de valoresHochiminh Stock Exchange
PaísHong Kong
Código postal- -
Telefone85221281188
Sitehttps://www.hutch-med.com/
Código da empresaHCM
Data de listagemMay 19, 2006
CEODr. Weiguo Su, Ph.D.
Executivos da empresa HUTCHMED (China) Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2024
FY2023
FY2022
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 25 de out
Atualizado em: sáb, 25 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Investment Management (US)
0.19%
AIA Group Ltd
0.18%
Outro
97.65%
Investidores
Investidores
Proporção
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Investment Management (US)
0.19%
AIA Group Ltd
0.18%
Outro
97.65%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
2.37%
Investment Advisor
0.70%
Research Firm
0.30%
Hedge Fund
0.24%
Individual Investor
0.12%
Sovereign Wealth Fund
0.01%
Outro
96.25%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
144
6.31M
3.62%
-5.66M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Schroder Investment Management (Singapore) Ltd.
1.77M
1.02%
-97.80K
-5.23%
Jun 30, 2025
Allianz Global Investors Asia Pacific Limited
878.74K
0.5%
-67.00K
-7.08%
Jun 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
805.63K
0.46%
-166.36K
-17.12%
Jun 30, 2025
State Street Investment Management (US)
328.79K
0.19%
-8.07K
-2.40%
Jun 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
289.13K
0.17%
+195.22K
+207.86%
Jun 30, 2025
M&G Investment Management Ltd.
259.62K
0.15%
+924.00
+0.36%
Jun 30, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Jane Street Capital, L.L.C.
175.96K
0.1%
-46.28K
-20.82%
Jun 30, 2025
Amundi Asset Management, SAS
157.43K
0.09%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Tema Oncology ETF
0.92%
National Security Emerging Markets Index ETF
0.42%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
Proporção0.92%
National Security Emerging Markets Index ETF
Proporção0.42%
Invesco Nasdaq Biotechnology ETF
Proporção0.05%
ProShares Ultra Nasdaq Biotechnology
Proporção0.05%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
Proporção0%
ActivePassive International Equity ETF
Proporção0%
SPDR Portfolio Developed World ex-US ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
